JP2022507218A - 癌を治療する方法 - Google Patents

癌を治療する方法 Download PDF

Info

Publication number
JP2022507218A
JP2022507218A JP2021525682A JP2021525682A JP2022507218A JP 2022507218 A JP2022507218 A JP 2022507218A JP 2021525682 A JP2021525682 A JP 2021525682A JP 2021525682 A JP2021525682 A JP 2021525682A JP 2022507218 A JP2022507218 A JP 2022507218A
Authority
JP
Japan
Prior art keywords
bfl
cancer
mcl
cdk9
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021525682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507218A5 (enExample
Inventor
シダード，ジャスティン
ボイコ，スコット
ドゥルー，リサ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2022507218A publication Critical patent/JP2022507218A/ja
Publication of JP2022507218A5 publication Critical patent/JP2022507218A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021525682A 2018-11-14 2019-11-13 癌を治療する方法 Pending JP2022507218A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862767215P 2018-11-14 2018-11-14
US62/767,215 2018-11-14
PCT/EP2019/081145 WO2020099470A1 (en) 2018-11-14 2019-11-13 Methods of treating cancer

Publications (2)

Publication Number Publication Date
JP2022507218A true JP2022507218A (ja) 2022-01-18
JP2022507218A5 JP2022507218A5 (enExample) 2022-11-18

Family

ID=68583377

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021525682A Pending JP2022507218A (ja) 2018-11-14 2019-11-13 癌を治療する方法

Country Status (6)

Country Link
US (1) US20220008392A1 (enExample)
EP (1) EP3881075A1 (enExample)
JP (1) JP2022507218A (enExample)
CN (1) CN112997078A (enExample)
TW (2) TWI810397B (enExample)
WO (1) WO2020099470A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7900421B2 (ja) 2021-06-11 2026-08-04 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗がん剤との組み合わせ
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合
IT202400003478A1 (it) * 2024-02-19 2025-08-19 Sbarro Health Res Organization Inc Cdk9 per uso nella determinazione della reattivita' di un tumore a un chemioterapico o per uso nel trattamento del cancro

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016252609B2 (en) * 2015-04-20 2022-06-30 Sumitomo Pharma Oncology, Inc. Predicting response to alvocidib by mitochondrial profiling
TR201909286T4 (tr) 2015-06-29 2019-07-22 Astrazeneca Ab CDK9 inhibitörleri olarak polisiklik amid türevleri.
CR20180499A (es) 2016-04-22 2019-01-25 Astrazeneca Ab Inhibidores de mcl1 macrocicliclos para tratar el cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RES., vol. Vol. 77, No. 13_Supplement, JPN6023035078, 2017, pages 4295, ISSN: 0005309441 *
ONCOTARGETS THER., vol. 11, JPN6023035076, 2018, pages 7301 - 7314, ISSN: 0005309443 *
SCI. REP., vol. 7, no. 1, JPN6023035077, 2017, pages 1 - 11, ISSN: 0005309442 *

Also Published As

Publication number Publication date
TW202033192A (zh) 2020-09-16
US20220008392A1 (en) 2022-01-13
TW202344250A (zh) 2023-11-16
CN112997078A (zh) 2021-06-18
WO2020099470A1 (en) 2020-05-22
TWI810397B (zh) 2023-08-01
EP3881075A1 (en) 2021-09-22

Similar Documents

Publication Publication Date Title
US20230255962A1 (en) Combination of a btk inhibitor and an inhibitor of cdk9 to treat cancer
Bill et al. SAR405838: a novel and potent inhibitor of the MDM2: p53 axis for the treatment of dedifferentiated liposarcoma
Lun et al. Disulfiram when combined with copper enhances the therapeutic effects of temozolomide for the treatment of glioblastoma
Christoph et al. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo
Bachmann et al. DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells
Costa et al. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor
Cassaday et al. A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma
Galimberti et al. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe
EP3213752B1 (en) Composition for treating cancer stem cells
WO2015198266A1 (en) Intermittent dosing of mdm2 inhibitor
Yuan et al. TIPE3 is a regulator of cell apoptosis in glioblastoma
US20230233565A1 (en) A treatment approach involving kif18a inhibition for chromosomally unstable tumors
TWI810397B (zh) 治療癌症之方法
WO2017086332A1 (ja) 間葉系ｋｒａｓ変異型がん治療剤
KR20210005182A (ko) 암 치료를 위한 조합
Hirai et al. Effects of combined therapeutic targeting of AXL and ATR on pleural mesothelioma cells
George et al. Loss of p21Waf1/Cip1/Sdi1 enhances intestinal stem cell survival following radiation injury
Valinciute et al. Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
Zhang et al. Compound 331 selectively induces glioma cell death by upregulating miR-494 and downregulating CDC20
KR20170071393A (ko) 방사선 저항성 진단용 조성물 및 이의 용도
US10144723B2 (en) Treatment of solid tumors by inhibiting MRK/ZAK
Castelletti et al. The quassinoid derivative NBT-272 targets both the AKT and ERK signaling pathways in embryonal tumors
Lu et al. EGFR suppression contributes to growth inhibitory activity of G-quadruplex ligands in non-small cell lung cancers
Colemon et al. ABL Kinases Modulate EZH2 Phosphorylation and Signaling in Metastatic Triple Negative Breast Cancer
Abbasian et al. Sirtuin1 and Chronic Myeloid Leukemia: a Comprehensive Glance at Drug Resistance.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240423